Zai Lab (NASDAQ:ZLAB – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Zai Lab to similar businesses based on the strength of its institutional ownership, dividends, profitability, analyst recommendations, valuation, risk and earnings.
Analyst Recommendations
This is a summary of current recommendations for Zai Lab and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zai Lab | 1 | 1 | 4 | 1 | 2.71 |
| Zai Lab Competitors | 9931 | 15320 | 45696 | 1605 | 2.54 |
Zai Lab presently has a consensus target price of $37.25, indicating a potential upside of 58.71%. As a group, “Biotechnology” companies have a potential upside of 131.88%. Given Zai Lab’s competitors higher probable upside, analysts clearly believe Zai Lab has less favorable growth aspects than its competitors.
Earnings & Valuation
This table compares Zai Lab and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Zai Lab | $441.73 million | -$175.54 million | -13.11 |
| Zai Lab Competitors | $715.39 million | $10.31 million | -18.32 |
Zai Lab’s competitors have higher revenue and earnings than Zai Lab. Zai Lab is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Zai Lab and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zai Lab | -44.91% | -31.15% | -18.17% |
| Zai Lab Competitors | -12,319.70% | -407.93% | -30.95% |
Insider & Institutional Ownership
41.7% of Zai Lab shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 4.9% of Zai Lab shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk and Volatility
Zai Lab has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Zai Lab’s competitors have a beta of -1.84, indicating that their average share price is 284% less volatile than the S&P 500.
Summary
Zai Lab beats its competitors on 7 of the 13 factors compared.
About Zai Lab
Zai Lab is a biopharmaceutical company that discovers, develops and commercializes medicines for patients with serious diseases. Its research and development programs focus on oncology, immunology, neuroscience and infectious diseases. Founded in 2014 by biopharmaceutical executive Samantha Du, the company is headquartered in Shanghai and operates in China and the United States. It advances its own drug candidates and works with international partners to develop and bring therapies to market. Zai Lab’s portfolio includes medicines and development programs for cancers and other conditions, including therapies introduced through licensing and collaboration agreements.
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.
